placeholder newsslider

News in Detail

PolyActiva offers results of Phase IIa study of ocular implant

PolyActiva Pty Ltd. announced that the Phase IIa study of its PA5108 ocular implant for the treatment of primary open-angle glaucoma (POAG) met both the study's primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort.